No accelerated approval for AbbVie's Rova-T By: MarketMinute.com Stock News March 22, 2018 at 17:39 PM EDT AbbVie Inc. (NYSE: ABBV) will not pursue accelerated approval for Rova-T to treat small cell lung cancer. The stock price crashed $14.35 to close at $98.10. Related Stocks: AbbVie